CENTRAL TRUST Co bought a new position in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the first quarter, HoldingsChannel reports. The firm bought 8,830 shares of the company’s stock, valued at approximately $1,741,000.
Other large investors have also recently modified their holdings of the company. Vaughan David Investments LLC IL purchased a new stake in AstraZeneca during the 4th quarter valued at $88,367,000. Cidel Asset Management Inc. purchased a new position in AstraZeneca during the first quarter worth $55,095,000. Captrust Financial Advisors purchased a new position in AstraZeneca during the fourth quarter worth $24,965,000. Azimuth Capital Investment Management LLC bought a new position in AstraZeneca during the fourth quarter valued at $20,440,000. Finally, L & S Advisors Inc bought a new position in AstraZeneca during the fourth quarter valued at $14,863,000. Institutional investors own 40.87% of the company’s stock.
AstraZeneca Price Performance
Shares of AZNCF opened at $187.10 on Thursday. AstraZeneca PLC has a twelve month low of $122.26 and a twelve month high of $195.00. The company’s fifty day simple moving average is $187.10 and its 200-day simple moving average is $186.19.
About AstraZeneca
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Recommended Stories
- Five stocks we like better than AstraZeneca
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
